Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States

By afschroeder • November 15, 2025

Charles-Schoeman C, Zueger P, McDearmon-Blondell E, Fang S, Peng Y, Oishi T, Jain M, Tesser J. Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a First-Line Tumor Necrosis Factor Inhibitor in the United States. Rheumatol Ther. 2025 Nov 14. doi: 10.1007/s40744-025-00808-z. Epub ahead of print. PMID: 41239038.

Tags: Biologic disease-modifying antirheumatic drug(bDMARD), Clinical Disease Activity Index(CDAI), Publications, Rheumatoid arthritis(RA), Rheumatology, Tumor necrosis factor inhibitor(TNFi)

Extreme Heat, Social Factors, and Mortality Among California Veterans With Cardiometabolic Disease

Shannon EM, Chen L, Yuan A, Chary A, Gabrielian S, Eisenman DP, Washington DL. Extreme Heat, Social Factors, and Mortality Among California Veterans With Cardiometabolic[...]

Differences in Retirement Knowledge and Financial Preparedness between Hispanic and Non-Hispanic White Older Adults in the United States

Blanco LR, Choi A, Hays RD. Differences in Retirement Knowledge and Financial Preparedness between Hispanic and Non-Hispanic White Older Adults in the United States. Gerontologist.[...]

Multi-omics analysis reveal clinical-gut-brain interactions in female ibs patients with adverse childhood experiences

Binod M, Chang L, Hung MW, Dong TS, Kilpatrick LA, Tomasevic A, Choy M, Shin A, Mayer EA, Church A. Multi-omics analysis reveal clinical-gut-brain interactions[...]